Payment overview · 2025
General Payments
$21.10
1 reported records · 1 companies
Healthcare provider profile · identity verified
Salman Lateef, MD
Allopathic & Osteopathic Physicians|Hospitalist · MECHANICSBURG, PA · NPI 1609975267
Verified facts
What the public records show
CMS Open Payments records show Salman Lateef, MD received $21.10 in general payments during 2025 across 1 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Nuedexta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $21.10 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $21.10 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $21.10 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1308 | 129 |
| Gabapentin | Gabapentin | 825 | 73 |
| Amlodipine Besylate | Amlodipine Besylate | 815 | 67 |
| Furosemide | Furosemide | 675 | 89 |
| Levothyroxine Sodium | Levothyroxine Sodium | 659 | 69 |
| Sertraline Hcl | Sertraline Hcl | 586 | 41 |
| Pantoprazole Sodium | Pantoprazole Sodium | 490 | 64 |
| Lisinopril | Lisinopril | 461 | 51 |
| Metoprolol Succinate | Metoprolol Succinate | 461 | 49 |
| Eliquis | Apixaban | 441 | 61 |
| Metoprolol Tartrate | Metoprolol Tartrate | 411 | 55 |
| Quetiapine Fumarate | Quetiapine Fumarate | 377 | 31 |
| Escitalopram Oxalate | Escitalopram Oxalate | 341 | 27 |
| Metformin Hcl | Metformin Hcl | 323 | 31 |
| Divalproex Sodium | Divalproex Sodium | 318 | 21 |
| Tamsulosin Hcl | Tamsulosin Hcl | 313 | 45 |
| Carvedilol | Carvedilol | 304 | 29 |
| Potassium Chloride | Potassium Chloride | 301 | 40 |
| Fluoxetine Hcl | Fluoxetine Hcl | 268 | 15 |
| Levetiracetam | Levetiracetam | 252 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 247 | 41 |
| Omeprazole | Omeprazole | 246 | 19 |
| Trazodone Hcl | Trazodone Hcl | 237 | 20 |
| Simvastatin | Simvastatin | 236 | 23 |
| Buspirone Hcl | Buspirone Hcl | 227 | 27 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 219 | 21 |
| Mirtazapine | Mirtazapine | 214 | 31 |
| Famotidine | Famotidine | 199 | 30 |
| Lamotrigine | Lamotrigine | 184 | suppressed |
| Losartan Potassium | Losartan Potassium | 169 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 168 | 20 |
| Allopurinol | Allopurinol | 156 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 150 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 145 | 28 |
| Finasteride | Finasteride | 138 | 15 |
| Donepezil Hcl | Donepezil Hcl | 136 | 20 |
| Glipizide | Glipizide | 133 | suppressed |
| Memantine Hcl | Memantine Hcl | 119 | 15 |
| Spironolactone | Spironolactone | 118 | 13 |
| Baclofen | Baclofen | 115 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 114 | 12 |
| Glimepiride | Glimepiride | 114 | 11 |
| Jardiance | Empagliflozin | 108 | 13 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 108 | 14 |
| Aripiprazole | Aripiprazole | 107 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 107 | 12 |
| Tradjenta | Linagliptin | 106 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 100 | 16 |
| Bumetanide | Bumetanide | 99 | 19 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 99 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 96 | 13 |
| Lorazepam | Lorazepam | 94 | 39 |
| Duloxetine Hcl | Duloxetine Hcl | 93 | 18 |
| Warfarin Sodium | Warfarin Sodium | 91 | 20 |
| Risperidone | Risperidone | 88 | 14 |
| Torsemide | Torsemide | 78 | suppressed |
| Xarelto | Rivaroxaban | 77 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 73 | suppressed |
| Myrbetriq | Mirabegron | 72 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 69 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 67 | suppressed |
| Calcitriol | Calcitriol | 64 | suppressed |
| Latanoprost | Latanoprost | 64 | 13 |
| Olanzapine | Olanzapine | 63 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 59 | 35 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 58 | suppressed |
| Fenofibrate | Fenofibrate | 57 | suppressed |
| Paliperidone Er | Paliperidone | 57 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 56 | 41 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 55 | 55 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 53 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 53 | suppressed |
| Celecoxib | Celecoxib | 52 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 51 | suppressed |
| Topiramate | Topiramate | 51 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 50 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 50 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 50 | 30 |
| Cilostazol | Cilostazol | 49 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 48 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 48 | 44 |
| Nortriptyline Hcl | Nortriptyline Hcl | 48 | suppressed |
| Sucralfate | Sucralfate | 47 | 11 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 46 | 30 |
| Amiodarone Hcl | Amiodarone Hcl | 44 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 44 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 43 | 20 |
| Januvia | Sitagliptin Phosphate | 43 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 41 | 12 |
| Doxepin Hcl | Doxepin Hcl | 40 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 39 | 14 |
| Pregabalin | Pregabalin | 37 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 36 | 13 |
| Farxiga | Dapagliflozin Propanediol | 35 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 35 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 34 | 14 |
| Solifenacin Succinate | Solifenacin Succinate | 33 | suppressed |
| Alprazolam | Alprazolam | 32 | suppressed |
| Prednisone | Prednisone | 32 | 17 |
| Dapagliflozin | Dapagliflozin Propanediol | 31 | suppressed |
| Ezetimibe | Ezetimibe | 31 | 12 |
| Methocarbamol | Methocarbamol | 31 | suppressed |
| Trulicity | Dulaglutide | 31 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 30 | 21 |
| Novolog Flexpen | Insulin Aspart | 30 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 28 | 12 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 28 | suppressed |
| Brilinta | Ticagrelor | 27 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 27 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 27 | 20 |
| Cephalexin | Cephalexin | 26 | 21 |
| Diltiazem Hcl | Diltiazem Hcl | 26 | suppressed |
| Hydrocortisone | Hydrocortisone | 26 | 12 |
| Lansoprazole | Lansoprazole | 26 | suppressed |
| Nyamyc | Nystatin | 26 | 15 |
| Nystatin | Nystatin | 26 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 25 | suppressed |
| Dutasteride-Tamsulosin | Dutasteride/Tamsulosin Hcl | 24 | suppressed |
| Lacosamide | Lacosamide | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 24 | suppressed |
| Creon | Lipase/Protease/Amylase | 23 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 23 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 23 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 23 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 23 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 22 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 22 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 21 | suppressed |
| Clonazepam | Clonazepam | 20 | 12 |
| Ketoconazole | Ketoconazole | 20 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 20 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 19 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 18 | 18 |
| Prednisolone Acetate | Prednisolone Acetate | 18 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 17 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Methimazole | Methimazole | 17 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 16 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 16 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 11 |
| Timolol Maleate | Timolol Maleate | 16 | suppressed |
| Atenolol | Atenolol | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 15 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Sotalol | Sotalol Hcl | 15 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 14 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Tacrolimus | Tacrolimus | 14 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 13 | suppressed |
| Budesonide | Budesonide | 13 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Xifaxan | Rifaximin | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Clozapine | Clozapine | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Entacapone | Entacapone | 12 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Trospium Chloride | Trospium Chloride | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | 11 |
| Colestipol Hcl | Colestipol Hcl | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Simbrinza | Brinzolamide/Brimonidine Tart | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $21.10 · 1 records | Otsuka America Pharmaceutical, Inc. | REXULTI | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Otsuka America Pharmaceutical, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error